Extended Data Fig. 8: Receiver operating characteristics analysis of baseline HER2 status.

Summary of receiver operating characteristics (ROC) analysis of baseline HER2 status to predict the clinical benefit by pertuzumab plus trastuzumab. Baseline HER2 status included fluorescence in situ hybridization (FISH) HER2/CEP17 ratio, FISH HER2 copy number (CN), tissue NGS copy number (tCN), plasma copy number (pCN), and adjusted pCN (ApCN). The two-sided P value tests the null hypothesis that the area under the ROC curve is 0.5. Adjustments were not made for multiple comparisons. Threshold is determined as the point of the ROC curve which is closest to the perfect (1,0) coordinate.